Selectively activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon release, and slow gastric emptying
Improved Safety Profile: Studies have demonstrated that this peptide is able to help lower the occurrence of side effects related to the use of growth hormone, including insulin resistance, joint and muscle pain, and water retention
Batista, M
A typical protocol involves 100 mcg of each peptide administered simultaneously via separate subcutaneous injections (or reconstituted in the same syringe), two to three times daily
Results vary from person to person, and it typically takes several weeks of consistent use to notice changes in energy or skin appearance
Mild injection site reactions (redness, tenderness) were the most common reported effects, and these typically resolved within days of continued use